



Biogen to Present at Bernstein's 35th Annual Strategic Decisions Conference

May 21, 2019

Cambridge, MA, -- Biogen Inc. (Nasdaq: BII) announced today that it will present at Bernstein's 35th Annual Strategic Decisions Conference. The webcast will be live on Thursday, May 30, at 10:00 a.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com/investors. An archived version of the webcast will be available following the presentation.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer's disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

Contact:

Karen Jewell
Investor Relations
Biogen
781-464-2442